A View on Drug Development for Cancer Prevention

Author:

Reynolds Andrew R.1ORCID,Moschetta Michele1ORCID,Yohannes Alula R.2ORCID,Walcott Farzana2ORCID,Ashford Marianne3ORCID,Szucs Zoltan1ORCID,Sarbajna Tina4ORCID,Hadfield James1ORCID,Harrison Eden2ORCID,Challis Benjamin G.5ORCID,Hernandez Amaya Gasco2ORCID,Schiavon Gaia1ORCID,Germa Caroline2ORCID,Zorenyi Gyorgy6ORCID,Crean Barry3ORCID,Galbraith Susan2ORCID

Affiliation:

1. 1Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

2. 2Oncology R&D, AstraZeneca, Gaithersburg, Maryland.

3. 3Pharmaceutical Sciences R&D, AstraZeneca, Cambridge, United Kingdom.

4. 4Oncology Business Unit, AstraZeneca, Cambridge, United Kingdom.

5. 5Biopharmaceutical R&D, AstraZeneca, Cambridge, United Kingdom.

6. 6Patient Safety, AstraZeneca, Cambridge, United Kingdom.

Abstract

Abstract Despite some notable successes, there are still relatively few agents approved for cancer prevention. Here we review progress thus far in the development of medicines for cancer prevention, and we outline some key concepts that could further enable or accelerate drug development for cancer prevention in the future. These are summarized under six key themes: (i) unmet clinical need, (ii) patient identification, (iii) risk stratification, (iv) pharmacological intervention, (v) clinical trials, and (vi) health care policy. These concepts, if successfully realized, may help to increase the number of medicines available for cancer prevention. Significance: The huge potential public health benefits of preventing cancer, combined with recent advances in the availability of novel early detection technologies and new treatment modalities, has caused us to revisit the opportunities and challenges associated with developing medicines to prevent cancer. Here we review progress in the field of developing medicines to prevent cancer to date, and we present a series of ideas that might help in the development of more medicines to prevent cancer in the future.

Funder

AstraZeneca

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3